|
2021, Vol. 30(1): 23-28 DOI: 10.3760/cma.j.cn113030-20200710-00353 | ||
Multicenter 5-year survival analysis of weekly Endostar combined with concurrent chemoradiotherapy for unresectable locally advanced non-small cell lung cancer | ||
Ma Honglian1, Peng Fang2, Zhai Yirui3, Bao Yong2, Xu Yujin1, Zhao Lujun4, Li Dongming5, Hui Zhouguang6, Xu Liming4, Hu Xiao1, Wang Lyuhua3, Chen Ming1 | ||
1Department of Radiation Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou 310022,China; 2Department of Radiation Oncology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China; 3Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; 4Department of Radiation Oncology, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China; 5Department of Radiotherapy, Peking University Cancer Hospital, Beijing 100142, China; 6Department of Special Medical, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China |
||
Received 2020-07-10 Revised null | ||
Supporting info | ||
null | ||
|